MAI Capital Management Purchases 957 Shares of Stryker Corporation $SYK

MAI Capital Management lifted its position in shares of Stryker Corporation (NYSE:SYK) by 0.9% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 108,032 shares of the medical technology company’s stock after purchasing an additional 957 shares during the period. MAI Capital Management’s holdings in Stryker were worth $40,215,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Elefante Mark B bought a new position in shares of Stryker during the fourth quarter worth approximately $337,000. Mogy Joel R Investment Counsel Inc. increased its stake in shares of Stryker by 3.4% during the first quarter. Mogy Joel R Investment Counsel Inc. now owns 98,216 shares of the medical technology company’s stock worth $36,561,000 after purchasing an additional 3,218 shares during the period. Ferguson Wellman Capital Management Inc. increased its stake in shares of Stryker by 1.9% during the first quarter. Ferguson Wellman Capital Management Inc. now owns 174,871 shares of the medical technology company’s stock worth $65,096,000 after purchasing an additional 3,341 shares during the period. Harbor Capital Advisors Inc. bought a new position in shares of Stryker during the first quarter worth approximately $1,840,000. Finally, Mar Vista Investment Partners LLC increased its stake in shares of Stryker by 10.2% during the first quarter. Mar Vista Investment Partners LLC now owns 90,187 shares of the medical technology company’s stock worth $33,572,000 after purchasing an additional 8,353 shares during the period. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Needham & Company LLC raised their price objective on Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Citigroup reaffirmed a “buy” rating and issued a $455.00 target price (up previously from $443.00) on shares of Stryker in a report on Thursday, May 22nd. JMP Securities reissued a “market perform” rating on shares of Stryker in a report on Monday, May 5th. Sanford C. Bernstein set a $450.00 target price on Stryker in a research report on Monday, May 5th. Finally, Wells Fargo & Company raised their target price on Stryker from $435.00 to $445.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Fifteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $430.10.

Stryker Stock Performance

Shares of Stryker stock opened at $391.48 on Friday. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The firm has a market capitalization of $149.67 billion, a price-to-earnings ratio of 51.85, a PEG ratio of 2.85 and a beta of 0.91. The business has a 50-day simple moving average of $389.26 and a 200 day simple moving average of $379.39. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.13 EPS for the quarter, beating analysts’ consensus estimates of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The business had revenue of $6.02 billion during the quarter, compared to analyst estimates of $5.92 billion. During the same period in the previous year, the company posted $2.81 EPS. The firm’s revenue was up 11.1% compared to the same quarter last year. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date of this dividend is Tuesday, September 30th. Stryker’s payout ratio is presently 44.50%.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Viju Menon sold 500 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider directly owned 12,511 shares of the company’s stock, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.